NCT01094093 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2010

Primary Completion Date

July 26, 2011

Study Completion Date

July 26, 2011

Conditions

Psoriasis

Interventions

DRUG

AMG 139

Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).

Trial Locations (4)

1010

Auckland Clinical Studies Ltd, Grafton

3004

Nucleus Network Limited, Melbourne

4006

QPharm Pty Limited, Herston

SA500

Clinical Medical and Analytical eXcellence (CMAX), Adelaide